INTEGRATED FILING — Other than Banks



General information about company

Scrip code 000000
NSE Symbol MEDIORG
MSEI Symbol NOTLISTED
ISIN INE0PE401018
Name of Company MEDICAMEN ORGANICS LIMITED
Type of company SME
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 29-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 24-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Half Yearly
Reporting Quarter Yearly
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 29-May-2025   15:00:00
End date and time of board meeting 29-May-2025   18:15:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
(III) Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-04-03
Indicate Company website link for updated RPT policy of the Company https://www.medicamenorganics.com/policies/
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 2
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
The company has not defaulted in payment / repayment of loan and debt securities.


Financial Results — Other than Bank
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Oct-2024 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Revenue From Operations
Revenue from operations 204772000 370877000
Other income 521000 950000
Total Income 205293000 371827000
2 Expenses
(a) Cost of materials consumed 124888000 222454000
(b) Purchases of stock-in-trade 0 0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -9519000 -8079000
(d) Employee benefit expense 19128000 36591000
(e) Finance costs 2910000 5127000
(f) Depreciation and amortisation expense 3728000 7368000
(g) Other Expenses
1 Other Expenses 24232000 31236000
2 Direct Expenses 17943000 33261000
Total other expenses 42175000 64497000
Total expenses 183310000 327958000
3 Profit before exceptional and extraordinary items and tax 21983000 43869000
4 Exceptional items 0 0
5 Profit before extraordinary items and tax 21983000 43869000
6 Extraordinary items 0 0
7 Profit before tax 21983000 43869000
8 Tax Expense
Current tax 5273000 11417000
Deferred tax -891000 -255000
Total tax expenses 4382000 11162000
9 Net Profit Loss for the period from continuing operations 17601000 32707000
10 Profit (loss) from discontinuing operations before tax 0 0
11 Tax expense of discontinuing operations 0 0
12 Net profit (loss) from discontinuing operation after tax 0 0
13 Profit (loss) for period before minority interest 17601000 32707000
14 Share of profit (loss) of associates
15 Profit (loss) of minority interest
16 Net profit (Loss) for the period 17601000 32707000
17 Details of equity share capital
Paid-up equity share capital 117000000 117000000
Face value of equity share capital 10 10
18 Reserves excluding revaluation reserve 172749000
19 Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 1.5 2.98
Diluted earnings (loss) per share from continuing and discontinued operations 1.5 2.98
20 Debt equity ratio
21 Debt service coverage ratio
22 Interest service coverage ratio
23 Disclosure of notes on financial results


Remarks
20 Debt equity ratio
21 Debt service coverage ratio
22 Interest service coverage ratio


Cash flow statement — indirect
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
1 Statement of cash flows
Cash flows from used in operating activities
Profit before extraordinary items and tax 43869000
2 Adjustments for reconcile profit (loss)
Adjustments to profit (loss)
Adjustments for finance costs 5127000
Adjustments for depreciation and amortisation expense 5973000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for unrealised foreign exchange losses gains 0
Adjustments for dividend income 0
Adjustments for share-based payments 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items -948000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments to profit (loss) 10152000
3 Adjustments for working capital
Adjustments for decrease (increase) in inventories -13467000
Adjustments for decrease (increase) in trade receivables -80521000
Adjustments for decrease (increase) in other current assets -47696000
Adjustments for increase (decrease) in trade payables 45883000
Adjustments for increase (decrease) in other current liabilities 2237000
Adjustments for provisions -8621000
Total adjustments for working capital -102185000
Total adjustments for reconcile profit (loss) -92033000
Net cash flows from (used in) operations -48164000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 944000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities before extraordinary items -49108000
Proceeds from extraordinary items 0
Payment for extraordinary items 0
Net cash flows from (used in) operating activities -49108000
4 Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 2700000
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property plant and equipment 0
Purchase of property plant and equipment 24482000
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 948000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Proceeds from government grants 0
Net cash flows from (used in) investing activities before extraordinary items -26234000
Proceeds from extraordinary items 0
Payment for extraordinary items 0
Net cash flows from (used in) investing activities -26234000
Cash flows from used in financing activities
Proceeds from issuing shares 105400000
Proceeds from issuing other equity instruments 7500000
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings -5231000
Repayments of borrowings 39000
Dividends paid 0
Interest paid 5127000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities before extraordinary items 102503000
Proceeds from extraordinary items 0
Payment for extraordinary items 0
Net cash flows from (used in) financing activities 102503000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 27161000
6 Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents 27161000
Cash and cash equivalents cash flow statement at beginning of period 5530000
Cash and cash equivalents cash flow statement at end of period 32691000


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Equity and liabilities
1 Shareholders' funds
Share capital 117000000
Reserves and surplus 172749000
Money received against share warrants 7500000
Total shareholders' funds 297249000
2 Share application money pending allotment 0
3 Deferred government grants
4 Minority interest
5 Non-current liabilities
Long-term borrowings 1575000
Deferred tax liabilities (net) 11599000
Foreign currency monetary item translation difference liability account
Other long-term liabilities
Long-term provisions 2534000
Total non-current liabilities 15708000
6 Current liabilities
Short-term borrowings 119720000
Trade Payables
(A) Total outstanding dues of micro enterprises and small enterprises 10875000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 105805000
Total Trade payable 116680000
Other current liabilities 12830000
Short-term provisions 12260000
Total current liabilities 261490000
Total equity and liabilities 574447000
Assets
1 Non-current assets
i Property, Plant and Equipment and Intangible assets
Property, Plant and Equipment 101154000
Producing properties
Intangible assets 143000
Preproducing properties
Property, Plant and Equipment capital work-in-progress 22159000
Intangible assets under development or work-in-progress
Total Property, Plant and Equipment and Intangible assets 123456000
ii Non-current investments 2700000
v Deferred tax assets (net)
vi Foreign currency monetary item translation difference asset account
vii Long-term loans and advances 0
viii Other non-current assets 14118000
Total non-current assets 140274000
Current assets
Current investments 0
Inventories 74894000
Trade receivables 247522000
Cash and cash equivalents 32691000
Bank balance other than cash and cash equivalents 0
Short-term loans and advances 79066000
Other current assets
Total current assets 434173000
Total assets 574447000
Disclosure of notes on assets and liabilities


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Oct-2024 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets
Net Segment Asset
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities
Net Segment Liabilities
Disclosure of notes on segments




Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 N C Raj & Associates Yes 28-Feb-2026


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)
Mode of Fund Raising Public Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 28-Jun-2024
Amount Raised 105400000
Report filed for Quarter ended 31-Mar-2025
Monitoring Agency Not Applicable
Monitoring Agency Name, if applicable
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation
Comments of the Audit Committee after review
Comments of the auditors, if any
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Funding of expenses proposed to be incurred towards Product registration in the international markets NA 30000000 0 4162000 0
2 Plant updation and increase in production capacity NA 22500000 0 22500000 0
3 Funding working capital requirements of our Company NA 40000000 0 40000000 0
4 General corporate purposes NA 3900000 0 3900000 0
5 Issue Related Expenses NA 9000000 0 9000000 0


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (2)
Mode of Fund Raising Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 13-Mar-2025
Amount Raised 29999000
Report filed for Quarter ended 31-Mar-2025
Monitoring Agency Not Applicable
Monitoring Agency Name, if applicable
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation
Comments of the Audit Committee after review
Comments of the auditors, if any
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 (a) working capital requirements; and/or (b) general corporate purpose. NA 29999000 0 7500000 0 As on March 31, 2025, funds received against the warrants subscription money on 4,65,910 warrants amounted to Rs. 2,99,99,945, constituting 25% of the total funds raised. Out of the received funds, the Company has spent RS. 75,00,000 towards the objects disclosed in the offer document/Postal Ballot Notice.


Signatory Details
Name of signatory Bal Kishan Gupta
Designation of person Managing Director
Place New Delhi
Date 29-May-2025


Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Medicamen Organics Limited Grande Etoile Pharmaceuticals Limited The company has formed subsidiary with 50.96% shareholding Investment Not Applicable 2546000 0 2546000
2 Medicamen Organics Limited Grande Etoile Pharmaceuticals Limited Subsidiary Company Any other transaction Reimbursement of Expenses Not Applicable 272000 0 31000
3 Medicamen Organics Limited Depot Yego Pharmacy Limited The company has acquired 51% shareholding in the company Investment Not Applicable 168000 0 168000
4 Medicamen Organics Limited Redline Healthcare Private Limited Associate Concern Interest paid Not Applicable 89000 1494000 1069000
5 Medicamen Organics Limited Redline Healthcare Private Limited Director is a Partner Any other transaction Purchase of Second Hand Vehicle Not Applicable 1999000 0 0
6 Medicamen Organics Limited Redline Healthcare Private Limited Director is a Partner Any other transaction Transfer of Vehicle Loan Not Applicable 1569000 0 0
7 Medicamen Organics Limited Redline Healthcare Private Limited Director is a Partner Advance Not Applicable 11032000 0 11032000
8 Medicamen Organics Limited Redline Healthcare Private Limited Director is a Partner Purchase of goods or services Not Applicable 10651000 7538000 10651000
9 Medicamen Organics Limited Bal Kishan Gupta Managing Director Remuneration Not Applicable 1660000 254000 162000
10 Medicamen Organics Limited Bal Kishan Gupta Managing Director Any other transaction Loan Taken Not Applicable 31780000 65760000 71218000
11 Medicamen Organics Limited Bal Kishan Gupta Managing Director Any other transaction Loan Repaid Not Applicable 26323000 0 0
12 Medicamen Organics Limited Ritu Gupta Director's Wife Remuneration Not Applicable 671000 210000 80000
13 Medicamen Organics Limited Ritu Gupta Director's Wife Any other transaction Loan Taken Not Applicable 2070000 0 0
14 Medicamen Organics Limited Ritu Gupta Director's Wife Any other transaction Loan Repaid Not Applicable 2300000 0 0
15 Medicamen Organics Limited Ashutosh Gupta Whole-time Director Remuneration Not Applicable 837000 200000 184000
16 Medicamen Organics Limited Ashutosh Gupta Whole-time Director Any other transaction Loan Taken Not Applicable 117000 500000 0
17 Medicamen Organics Limited Ashutosh Gupta Whole-time Director Any other transaction Loan Repaid Not Applicable 642000 0 0
18 Medicamen Organics Limited Shivani Chopra Shareholder Remuneration Not Applicable 1655000 0 121000
19 Medicamen Organics Limited Shivani Chopra Shareholder Any other transaction Loan Taken Not Applicable 500000 0 0
20 Medicamen Organics Limited Shivani Chopra Shareholder Any other transaction Loan Repaid Not Applicable 500000 0 0
21 Medicamen Organics Limited BKG and Sons HUF Managing Director's HUF Any other transaction Loan Taken Not Applicable 2570000 0 0
22 Medicamen Organics Limited BKG and Sons HUF Managing Director's HUF Any other transaction Loan Repaid Not Applicable 2570000 0 0
23 Medicamen Organics Limited Shailesh Harimohan Gaur Past Executive Director Remuneration Not Applicable 823000 100000 0
24 Medicamen Organics Limited Brijesh Kumar Chaubey Executive Director Remuneration Not Applicable 654000 0 136000
25 Medicamen Organics Limited Jasbal Pharma LLP LLP in which Director is Partner Sale of goods or services Not Applicable 730000 100000 75000
Total value of transaction during the reporting period 104728000